Dimiter Stanchev Dimitrov

USPTO Granted Patents = 97 (Patent Applications = 34)

EPO Patents = 31 (Patent Applications = 55)

Average Co-Inventor Count = 3.4

ph-index = 9

Forward Citations = 239(Granted Patents)

Forward Citations (Not Self Cited) = 203(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Rockville, MD (US) (2007 - 2014)
Frederick, MD (US) (2008 - 2024)
Pittsburgh, PA (US) (2020 - 2024)

Company Filing History:

89 out of 3,539

The United States of America, As Represented by the Secretary, Department of Health and Human Services

patents

15 out of 40

Biomed Valley Discoveries, Inc.

patents

15 out of 37

Lentigen Technology, Inc.

patents

4. 5 out of 559

Memorial Sloan Kettering Cancer Center

patents

5. 3 out of 192

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

patents

6. 3 out of 2,660

Purdue Research Foundation

patents

7. 2 out of 1,187

The Scripps Research Institute

patents

8. 2 out of 607

The Hong Kong University of Science and Technology

patents

9. 2 out of 282

The Children's Hospital of Philadelphia

patents

10. 1 out of 1,863

University of Pittsburgh

patents

11. 1 out of 8,684

US Government As Represented by the Secretary of the Army

patents

12. 1 out of 1,217

The United States of America As Represented by the Department of Health

15. 1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...

Areas of Expertise:

Monoclonal Antibodies

Cancer Immunotherapy

Chimeric Antigen Receptors

Tumor-Associated Stroma

Fibroblast Growth Factor Receptor 4

CD38 Immunotherapy

Glypican 2

Antigen-Binding Proteins

CD22 Targeting

SARS-CoV-2

Combination Therapies

Anti-CD276 Antibodies

97 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12453780 - Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use (2025-10-28),

2. 12391958 - Compositions and methods for treating cancer with anti-CD38 immunotherapy (2025-08-19),

3. 12378321 - ADAM17 binding molecules and uses thereof (2025-08-05),

4. 12037404 - Human monoclonal antibodies against EphA4 and their use (2024-07-16),

5. 12037403 - Compositions and methods for treating cancer with anti-CD123 immunotherapy (2024-07-16),

6. 12018077 - Methods of treatments using antigen-binding proteins targeting CD56 (2024-06-25),

7. 12012455 - Human monoclonal antibodies specific for FLT3 and uses thereof (2024-06-18),

8. 11970528 - Compositions and methods for treating cancer with anti-mesothelin immunotherapy (2024-04-30),

9. 11939377 - Affinity matured CD22-specific monoclonal antibody and uses thereof (2024-03-26),

10. 11878052 - Compositions and methods for treating cancer with anti-CD22 immunotherapy (2024-01-23),

11. 11851498 - Anti-CD276 antibodies (B7H3) (2023-12-26),

12. 11814440 - Glypican 2 as a cancer marker and therapeutic target (2023-11-14),

13. 11807682 - M971 chimeric antigen receptors (2023-11-07),

14. 11708408 - Compositions and methods for treating cancer with anti-CD19 immunotherapy (2023-07-25),

15. 11702472 - Method of reducing mesothelin-expressing tumor burden by administration of T cells comprising mesothelin-targeted chimeric antigen receptors (2023-07-18),

Title: The Innovative Journey of Dimiter Stanchev Dimitrov

Introduction:

Dimiter Stanchev Dimitrov is a visionary inventor based in Frederick, MD (US) known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents:

Dimiter Stanchev Dimitrov holds several patents in the areas of artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and creativity.

Career Highlights:

With over two decades of experience in research and development, Dimiter Stanchev Dimitrov has worked for leading tech companies, where he spearheaded projects that have revolutionized industries and improved people's lives.

Collaborations:

Throughout his career, Dimiter Stanchev Dimitrov has collaborated with top researchers, engineers, and scientists from around the world, fostering a culture of innovation and excellence in all his projects.

Conclusion:

Dimiter Stanchev Dimitrov's relentless pursuit of innovation and his passion for creating solutions to complex challenges make him a true pioneer in the world of technology, inspiring the next generation of inventors to push the boundaries of what is possible.

This text is generated by artificial intelligence and may not be accurate.